Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Immutep S A S is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions. These actions are distributed among 4 distinct examiners and 4 distinct art units.
CHASE, CAROL ANN is the busiest examiner for this portfolio, managing 1 pending office action. Because each of the 4 distinct examiners is responsible for exactly 1 of the 4 pending office actions, the workload is perfectly balanced across the staff. No single examiner has more influence than another over the active matters.
The use of 4 distinct art units indicates a high degree of technical diversity in the pending applications. Practitioners must manage 4 separate examiner relationships across 4 different units. This fragmented prosecution landscape requires a coordinated strategy to ensure consistency, even though each action is being reviewed by a different individual. The reliance on 4 distinct examiners minimizes the impact of any single examiner's specific tendencies, including those of CHASE, CAROL ANN.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHASE, CAROL ANN | 1 | 41.9% | +84.9% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17607784 | ASSAYS | GAO, ASHLEY HARTMAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928048 | TREATMENT OF CANCER | DENT, ALANA HARRIS | 29d |
| 18570846 | TRIPLE COMBINATION THERAPY | CHASE, CAROL ANN | — |
| 17607828 | ANTI-LAG-3 BINDING MOLECULES | NICKOL, GARY B | — |
| 17607784 | ASSAYS | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1643 | 1 |
| 1600 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570846 | TRIPLE COMBINATION THERAPY | CHASE, CAROL ANN | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 17928048 | TREATMENT OF CANCER | DENT, ALANA HARRIS | 1643 | DP | Non-Final OA | 29d | Pending | Nov 28, 2022 |
| 17607828 | ANTI-LAG-3 BINDING MOLECULES | NICKOL, GARY B | 1600 | §112 | Final Rejection | — | Pending | Oct 29, 2021 |
| 17607784 | ASSAYS | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Non-Final OA | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmutep S A S has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Carol Ann Chase has the most, with 1 of Immutep S A S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
